BREAKING
Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 42 minutes ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 2 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 5 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 7 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 7 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 8 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 9 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 11 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 11 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 12 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 42 minutes ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 2 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 5 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 7 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 7 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 8 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 9 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 11 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 11 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 12 hours ago
ADVERTISEMENT
Market News

Endo International (ENDP): Q3 2019 Earnings Snapshot

— Endo International plc (NASDAQ: ENDP) reported Q3 2019 earnings of $0.60 per share, vs. $0.53 expected. — Revenues fell 2% to $729 million, vs. $709 million expected. — Specialty Products revenues increased 18% to $132 million. — Sterile Injectables revenues grew 11% to $264 million.   — FY19 revenues are expected to be between $2.86 billion […]

$ENDP November 5, 2019 1 min read

— Endo International plc (NASDAQ: ENDP) reported Q3 2019 earnings of $0.60 per share, vs. $0.53 expected.

— Revenues fell 2% to $729 million, vs. $709 million expected.

— Specialty Products revenues increased 18% to $132 million.

— Sterile Injectables revenues grew 11% to $264 million.  

— FY19 revenues are expected to be between $2.86 billion and $2.89 billion.  

ADVERTISEMENT

— FY19 adjusted EPS from continuing operations is expected to be $2.10 and $2.25.

— ENDP shares were down 3% in premarket hours on Tuesday.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

ADVERTISEMENT